Friess Associates LLC Catalyst Pharmaceuticals, Inc. Transaction History
Friess Associates LLC
- $59.9 Million
- Q2 2022
A detailed history of Friess Associates LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Friess Associates LLC holds 305,148 shares of CPRX stock, worth $7.1 Million. This represents 3.57% of its overall portfolio holdings.
Number of Shares
305,148
Previous 571,940
46.65%
Holding current value
$7.1 Million
Previous $4.74 Million
54.88%
% of portfolio
3.57%
Previous 2.53%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
97.8MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$435 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$196 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$145 Million2.3% of portfolio
-
State Street Corp Boston, MA5.8MShares$135 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$70.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.39B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...